Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Key Takeaways Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.

Johnson & Johnson, already a big player in ... Two years later, its label expanded to include bipolar depression. Caplyta is a small molecule formulated as a capsule taken once daily.

depression. Back in 2018, Johnson opened up about his struggles with mental health, showing fans that even the “big guy” isn’t invincible. It all started with a raw confession. Johnson ...

SINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

The deal would add to J & J’s portfolio lumateperone, an Intra-Cellular drug branded Caplyta, a pill that treats bipolar depression and schizophrenia. Analysts predict the drug’s sales could ...